Blood markers to predict chronic graft rejection after stem cell transplant
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study collects blood samples from patients who have survived at least 3 months after a stem cell transplant to identify markers that could predict chronic graft-versus-host disease (a condition where the transplanted cells attack the body). The goal is to develop a simple blood test that could help doctors catch and treat this complication earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received an allogeneic stem cell transplant (from a donor) more than 3 months ago
- You are 18 years old or older
- You tested negative for HIV, hepatitis B, and hepatitis C
- You have not had a previous stem cell transplant before this one
- You are able to cooperate with study visits and monitoring
- You are mentally and physically able to participate in the research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
This study follows patients who have had a stem cell transplant and developed chronic graft-versus-host disease (a condition where transplanted cells attack the body). Researchers will track your symptoms and collect blood samples to understand what affects how well patients do over time.
This trial checks if measuring a specific virus marker in your blood after a stem cell transplant can help predict or prevent transplant complications. You would have extra blood tests to guide your care.
This study tests a new blood test to help predict whether acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will come back after a stem cell transplant. Early detection could help doctors treat relapse sooner.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.